GlassScriptPhysician profile
Rory Dray Brienen
NPI 1194757377
$1,635.33
in general payments reported to CMS, 2019-2025
14 companies · $185 in 2025
The $185 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $105 · 2020: $16.53 · 2021: $246 · 2022: $159 · 2023: $302 · 2024: $622 · 2025: $185.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,109.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $442.48 | 2022-2025 | Durysta |
| Biotissue Holdings INC. | $316.24 | 2024 | |
| Bausch & Lomb Americas INC. | $285.89 | 2022-2025 | Infuse, Vyzulta, Biotrue One Day |
| Sight Sciences, INC. | $163.39 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $144.30 | 2019-2021 | |
| Alcon Vision LLC | $100.69 | 2023-2025 | Rocklatan |
| Sun Pharmaceutical Industries INC. | $44.16 | 2021-2023 | Cequa |
| Dompe US, INC. | $28.49 | 2024 | Oxervate |
| Genentech USA, INC. | $23.15 | 2025 | Vabysmo |
| Akorn Operating Company LLC | $20.41 | 2021 | |
| Rxsight INC | $17.68 | 2023 | Rxsight Injector Handpiece, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Allergan, INC. | $17.01 | 2022 | |
| Eyevance Pharmaceuticals LLC | $16.53 | 2020 | |
| Carl Zeiss Meditec USA, INC. | $14.91 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rory Brienen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.